Psoriasis Vulgaris Clinical Trial
Official title:
Incretin Effect in Patients With Psoriasis
Verified date | September 2023 |
Source | University Hospital, Gentofte, Copenhagen |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
To investigate the incretin effect and postprandial incretin responses in plasma in patients with psoriasis
Status | Completed |
Enrollment | 24 |
Est. completion date | September 11, 2015 |
Est. primary completion date | September 11, 2015 |
Accepts healthy volunteers | |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: no diabetes BMI < 27 kg/m^2 normal Glucose tolerance test at screening normal fasting plasma glucose no islet auto antibodies no hormonel contraception informed consent psoriasis vulgaris (PASI>8) (case not controls) Exclusion Criteria: other chronic inflammtory skin disease other chronic inflammatory disease pregnancy psychiatric illness |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Gentofte, Copenhagen |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incretin effect measured with Beta-cell secretory response | Incretineffect (%) = 100 % × (Beta-cell Secretory Response (OGTT) - Beta-cell Secretory Response (IIGI)) / Beta-cell Secretory Response (OGTT) | 0-180 minutes | |
Secondary | Insulin sensitivity measures | Matsudas insulin sensitivity index: (10,000 / vglucose minute 0 x insulin minute 0) (mean glucose (OGTT) x mean insulin OGTT)) | 0-180 minutes | |
Secondary | Concentration of Glucose-independent insulinotropic polypeptide | Evaluted as Area Under the Curve | 0-180 minutes | |
Secondary | Concentration of Glucagon-like peptide 1 | Evaluated as Area Under the Curve | 0-180 minuntes | |
Secondary | Concentration of Glucagon | Evaluated as Area Under the Curve | 0-180 minutes | |
Secondary | Concentration of Insulin | Evaluated as Area Under the Curve | 0-180 minutes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03669757 -
Clinical Trial to Assess Safety, Tolerability and the Pharmacodynamic Effect of Different Concentrations of a New Anti-inflammatory Substance in Subjects With Chronic Plaque Psoriasis
|
Phase 1 | |
Completed |
NCT03614078 -
A Study of PRCL-02 in Moderate to Severe Chronic Plaque Psoriasis
|
Phase 2 | |
Completed |
NCT03584360 -
Role of Topical Treatments in the Modulation of Skin Microbiome in Psoriatic Skin
|
Phase 2 | |
Recruiting |
NCT04994951 -
Pilot Study of Traditional Chinese Medicine (Qing-Re-Liang-Xue Decoction) as Complementary Medicine for Psoriasis Vulgaris of Blood-heat Syndrome.
|
Phase 2 | |
Completed |
NCT02888236 -
LEO 32731 for the Treatment of Moderate to Severe Psoriasis Vulgaris
|
Phase 2 | |
Completed |
NCT02533973 -
Long-term Treatment of Scalp Psoriasis With Xamiol® Gel in a Large Adult Chinese Population
|
Phase 4 | |
Completed |
NCT02193815 -
A 12 Day Study To Evaluate A Topical Drug To Treat Plaque Psoriasis
|
Phase 1 | |
Completed |
NCT02004847 -
Blue Light for Treating Psoriasis Vulgaris
|
N/A | |
Completed |
NCT01946386 -
A Vasoconstriction Study With LEO 90100
|
Phase 1 | |
Recruiting |
NCT01443338 -
Study Evaluating the Efficacy and Safety of Triptergium Wilfordii and Acitretin in Psoriasis Vulgaris - CHINA201002016-2
|
Phase 4 | |
Completed |
NCT01188928 -
LEO 80185 in the Treatment of Psoriasis Vulgaris on the Non-scalp Regions of the Body (Trunk and/or Limbs)
|
Phase 3 | |
Completed |
NCT00764751 -
Efficacy and Safety of LEO 19123 Cream in the Treatment of Psoriasis Vulgaris
|
Phase 2 | |
Completed |
NCT00236171 -
Evaluation of Topical Antipsoriatics in the Psoriasis Plaque Test
|
N/A | |
Completed |
NCT04541329 -
Predicting Inflammatory Skin Disease Response to IL-23 Blockade
|
Phase 4 | |
Not yet recruiting |
NCT06398106 -
Proactive TDM Versus Standard Use of Biologics in Psoriasis
|
Phase 4 | |
Recruiting |
NCT05390515 -
Psoriatic Immune Response to Tildrakizumab
|
Phase 4 | |
Recruiting |
NCT05892640 -
Low-Salt Diet Effect on Th17-Mediated Inflammation and Vascular Reactivity in Psoriasis
|
N/A | |
Recruiting |
NCT04950218 -
The Psoriasis Echo Study
|
||
Completed |
NCT05184348 -
Plexin B2 Gene Expression and Polymorphisms in Psoriasis
|
Phase 1 | |
Recruiting |
NCT04394936 -
An Explorative Psoriasis Biomarker Study
|
N/A |